Today's Date: February 3, 2023
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Affirm Holdings, Inc.   •   Introduction of Diagnostic and Supplemental Imaging Legislation Would Benefit Thousands of Marylanders   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NeoGenomics, Inc. (NE   •   Hyundai and TEN Advertising Develop Their First Asian American Campaign "My Love, My Son-in-Law" for the Tucson SUV   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of National Vision Ho   •   Government of Canada to support clean air and local economic growth by powering federal operations in Alberta and Saskatchewan w   •   Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behal   •   American Marketing Association San Diego Launches New Sandie Awards and Opens Call for Entries   •   Conemaugh Miners Medical Center and Conemaugh Meyersdale Medical Center Achieve Designation as Lifepoint Health National Quality   •   US Fertility founding partner Shady Grove Fertility (SGF) announces Egg Freezing for Surgical Residents Program in celebration o   •   Worldwide Shipments of Tablets and Chromebooks Declined Sharply in 2022, According to IDC Tracker   •   Scottsdale Tesla Drivers Club and PS Academy Arizona Work Together on Tesla Cybertruck Build   •   INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Invivyd, Inc. f/k/   •   Experiences of Black Women With Breast Cancer Highlight Need for Better Care, Improved Outcomes   •   TWO PUBLIC ALLIES ALUMNI JOIN THE NATIONAL BOARD OF DIRECTORS   •   The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veru Inc. (VERU)   •   RESIDES CEO COLETTE STEVENSON NAMED 2023 RISMEDIA REAL ESTATE NEWSMAKER   •   Urban One Inc's Reach Media Announces R&B Superstar Ralph Tresvant of New Edition as Host of "Love and R&B"   •   General Dynamics Elects Richard Clarke to Board of Directors   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Honda Motor Co., Ltd. with Losses of $100,000 to Contact t
Bookmark and Share

Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a Trial of Vosilasarm (EP0062) at SABCS

LONDON , December 05 /Businesswire/ - Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, will present a “Trial in Progress” poster detailing the design of a Phase 1/2 trial of vosilasarm (EP0062) in advanced breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas on Tuesday, 6 December from 5:00pm to 6:15pm CST.

Vosilasarm is a selective androgen receptor modulator (SARM) under development for the potential treatment of advanced breast cancer. This study is designed to further extend the evaluation of vosilasarm as a potential therapy for AR+/HER2–/ER+ advanced breast cancer, with the primary aim of identifying a recommended phase 2 dose (RP2D). Recruitment has commenced and the study will recruit up to 130 patients globally.


Presentation details


A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer


Professor Elgene Lim, Institute of Medical Research, University of New South Wales, Sydney, Australia;


Abstract number


Date and time

Tuesday December 6, 2022; 5:00 PM - 6:15 PM

Session name

Trial in Progress Session


Henry B. González Convention, San Antonio, Texas

Professor Hendrik-Tobias Arkenau, Global Head of Drug Development and Chief Medical Officer at Ellipses, said:

“Developing promising assets at speed is fundamental to the work of Ellipses, and we are excited to be presenting this ongoing study at such an important scientific conference. We look forward to presenting further details on this trial, including results, in the future.”

Dr Rajan Jethwa, CEO of Ellipses, said:

“The initiation of this trial for vosilasarm is another key milestone towards our goal of accelerating the development of promising cancer drugs. I am excited by the potential across our pipeline to make available much-needed drugs for patients with cancer.”

About vosilasarm / EP0062

Vosilasarm is an oral, non-steroidal, SARM currently being developed for the treatment of AR+/HER2-/ER+ advanced breast cancer. The efficacy and safety of vosilasarm has previously been investigated in a small Phase 1 clinical trial of AR+/HER2–/ER+ advanced breast cancer, and was demonstrated to have acceptable tolerability with preliminary evidence of clinical efficacy (LoRusso et al. Clinical Breast Cancer 2022 22;1 67-77).

About AR+/HER2–/ER+ advanced breast cancer

Despite recent progress, advanced ER+/HER2- breast cancer remains an area of high unmet medical need. It is estimated that 75-90% of advanced ER+ breast cancers are androgen receptor (AR) positive. It has been established that the AR acts as a tumour suppressor in multiple contexts of ER+ breast cancer, including where resistance to current endocrine-based regimens develops (Hickey et al. Nature Medicine 2021 27; 310-320). This provides the rationale for evaluating vosilasarm, an AR agonist, as a potential treatment strategy.

About Ellipses Pharma Limited

Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer medicines and treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimize the time it takes to advance lead products through clinical trials and reach patients.

For more information, please visit

STORY TAGS: Texas, Europe, United States, United Kingdom, North America, Conference, General Health, Other Health, Health, Pharmaceutical, Oncology,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News